Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Antengene Approved to Launch XPO1 Inhibitor for Multiple Myeloma

publication date: Dec 17, 2021

Shanghai Antengene announced that Xpovio® (selinexor), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE), was approved in China for relapsed or refractory multiple myeloma. It is China's first approved XPO1 inhibitor and Antengene's first approved product. The conditional approval is for second-line therapy in combination with dexamethasone. In 2018, Antengene in-licensed China rights to four novel oral drug candidates including Xpovio® from Boston's Karyopharm in an $162 million agreement. More details....

Stock Symbol: (NSDQ: KPTI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.